Regeneron Pharmaceuticals
REGN
$4.95 (0.65%)
1D
1W
3M
1Y
5Y
ALL
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 2 hours ago • REGN
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
CNBC Television • 3 days ago • REGN
Final Trades: Berkshire Hathaway, Regeneron, DocuSign and Leidos Holdings
GlobeNewsWire • 4 days ago • REGN
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
GlobeNewsWire • 4 days ago • REGN
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
The Motley Fool • 4 days ago • REGN
2 Top Growth Stocks to Buy on the Dip
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.
